View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
November 17, 2020

Tonix reports positive data from trial of TNX-1800 Covid-19 vaccine

Tonix Pharmaceuticals has reported positive preliminary results following the vaccination of non-human primates with its Covid-19 vaccine candidate, TNX-1800.

Tonix Pharmaceuticals has reported positive preliminary results following the vaccination of non-human primates with its Covid-19 vaccine candidate, TNX-1800.

Data showed that the live attenuated TNX-1800 induced a strong immune response to CoV-2 in non-human primates.

TNX-1800 is a live modified horsepox virus vaccine for percutaneous administration. It is engineered to express the SARS-CoV-2 spike protein and elicit a predominant T cell response.

Vaccine research is carried out in partnership with the Southern Research Institute, the University of Alberta.

The ongoing study is analysing TNX-1800, a modified horsepox virus encoding CoV-2 spike protein over TNX-801, a live horsepox virus vaccine at two doses.

Tonix Pharmaceuticals president and CEO Seth Lederman said: “We are pleased that all eight animals vaccinated with TNX-1800 manifested ‘takes’, a skin reaction which is a validated biomarker of functional T cell immunity, and that vaccination was associated with neutralising antibodies in each case.

“These results encourage us to advance TNX-1800 to human Phase I trials in 2021, when we expect to have Good Manufacturing Practice or cGMP, quality TNX-1800 available.”

Results showed that at day 14 after a single vaccination, all eight of the TNX-1800 vaccinated non-human primates made anti-CoV-2 neutralising antibodies.

The level of neutralising anti-CoV-2 antibody production was similar between the low and high dose TNX-1800 groups.

Furthermore, results showed that TNX-1800 was well tolerated at both doses.

Tonix now plans to conduct the second phase of the study, where the TNX-1800 vaccinated and control animals will be challenged with CoV-2.

The company earlier announced that its manufacturing partner is FUJIFILM Diosynth Biotechnologies.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena